| Summary: | Objective: This study aimed to determine the predictive value of first and second trimester screening test biomarkers in preeclampsia.
Methods: This was a retrospective case-control study. While 85 patients diagnosed with pre-eclampsia between January 2013-December 2016 constituted the study group, randomly assigned 93 patients with no additional obstetric problems constituted the control group. Demographic characteristics, laboratory results, obstetric outcomes, first and second trimester screening test results were collected from the hospital records.
Results: Of the 85 preeclamptic patients, 32 had mild, 53 had severe pre-eclampsia. When the preeclampsia group was compared with the control group, the low level of pregnancy associated plasma protein-A (PAPP-A) multiples of median (MoM), the high level of human chorionic gonadotropin (hCG) MoM and nuchal translucency (NT) MoM was found to be statistically significant. However, these markers have not been found to be clinically useful for the mild preeclampsia group compared with the severe preeclampsia group. A ROC curve was drawn to show the predictive role of NT MoM, hCG MoM and PAPP-A MoM for preeclampsia. The area under the curve (AUC) was 0.628+-0.042 [p=0.003; 95% confidence interval (CI): 0.545-0.711] for NT MoM and 0.697+-0.047 (p<0.001; 95% CI: 0.605-0.789) for hCG MoM. The AUC was 0.589+-0.044 (p=0.040; 95% CI: 0.503-0.676) for PAPP-A MoM. These results indicate that there were significant relationships between these variables and pre-eclampsia.
Conclusion: Low levels of PAPP-A MoM, high levels of hCG MoM and NT MoM are useful significant predictive markers for prediction of preeclampsia.
|
|---|